stoxline Quote Chart Rank Option Currency Glossary
  
Akero Therapeutics, Inc. (AKRO)
18.6  -0.06 (-0.32%)    05-30 15:03
Open: 18.89
High: 19.12
Volume: 573,370
  
Pre. Close: 18.66
Low: 18.41
Market Cap: 1,286(M)
Technical analysis
2024-05-30 2:42:13 PM
Short term     
Mid term     
Targets 6-month :  24.04 1-year :  25.99
Resists First :  20.58 Second :  22.26
Pivot price 19.86
Supports First :  17.87 Second :  14.87
MAs MA(5) :  18.79 MA(20) :  20.12
MA(100) :  22.72 MA(250) :  30.25
MACD MACD :  -0.8 Signal :  -0.7
%K %D K(14,3) :  25 D(3) :  22.4
RSI RSI(14): 39.6
52-week High :  58.38 Low :  11.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AKRO ] has closed above bottom band by 13.1%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 19.4 - 19.5 19.5 - 19.59
Low: 18.26 - 18.37 18.37 - 18.49
Close: 18.44 - 18.63 18.63 - 18.81
Company Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Headline News

Thu, 30 May 2024
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics - GlobeNewswire

Thu, 30 May 2024
AKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to ... - AccessWire

Thu, 30 May 2024
Quest Partners LLC Acquires Shares of 3219 Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Thu, 30 May 2024
Teacher Retirement System of Texas Has $240000 Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Wed, 29 May 2024
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire

Wed, 29 May 2024
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference - Yahoo Finance Australia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 69 (M)
Shares Float 46 (M)
Held by Insiders 5.4 (%)
Held by Institutions 99.2 (%)
Shares Short 8,180 (K)
Shares Short P.Month 9,470 (K)
Stock Financials
EPS -2.9
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.6
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -23.1 %
Return on Equity (ttm) -35.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.5
Qtrly Earnings Growth 0 %
Operating Cash Flow -145 (M)
Levered Free Cash Flow -94 (M)
Stock Valuations
PE Ratio -6.44
PEG Ratio 0.3
Price to Book value 1.93
Price to Sales 0
Price to Cash Flow -8.85
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android